Literature DB >> 23646235

Accurate Quantitation of Dystrophin Protein in Human Skeletal Muscle Using Mass Spectrometry.

Kristy J Brown1, Ramya Marathi, Alyson A Fiorillo, Eugene F Ciccimaro, Seema Sharma, David S Rowlands, Sree Rayavarapu, Kanneboyina Nagaraju, Eric P Hoffman, Yetrib Hathout.   

Abstract

Quantitation of human dystrophin protein in muscle biopsies is a clinically relevant endpoint for both diagnosis and response to dystrophin-replacement therapies for dystrophinopathies. A robust and accurate assay would enable the use of dystrophin as a surrogate biomarker, particularly in exploratory Phase 2 trials. Currently available methods to quantitate dystrophin rely on immunoblot or immunohistochemistry methods that are not considered robust. Here we present a mass spectrometry based approach to accurately quantitate dystrophin protein in a total protein extract from human muscle biopsies. Our approach uses a combination of stable isotope labeled dystrophin as a spike-in standard, gel electrophoresis and high precision mass spectrometry to detect and quantitate multiple peptides of dystrophin within a complex protein mixture. The method was found highly reproducible and linear over a wide dynamic range, detecting as low as 5% of dystrophin relative to the normal amount in healthy individuals.

Entities:  

Keywords:  Duchenne; Dystrophin; Mass spectrometry; Quantitation; Stable isotope

Year:  2012        PMID: 23646235      PMCID: PMC3642779          DOI: 10.4172/1948-593X.S7-001

Source DB:  PubMed          Journal:  J Bioanal Biomed


  27 in total

Review 1.  Sample preparation methods for mass spectrometric peptide mapping directly from 2-DE gels.

Authors:  O N Jensen; M Wilm; A Shevchenko; M Mann
Journal:  Methods Mol Biol       Date:  1999

Review 2.  The status of exon skipping as a therapeutic approach to duchenne muscular dystrophy.

Authors:  Qi-Long Lu; Toshifumi Yokota; Shin'ichi Takeda; Luis Garcia; Francesco Muntoni; Terence Partridge
Journal:  Mol Ther       Date:  2010-10-26       Impact factor: 11.454

Review 3.  Restoring dystrophin expression in duchenne muscular dystrophy muscle progress in exon skipping and stop codon read through.

Authors:  Eric P Hoffman; Abby Bronson; Arthur A Levin; Shin'ichi Takeda; Toshifumi Yokota; Andreas R Baudy; Edward M Connor
Journal:  Am J Pathol       Date:  2011-05-23       Impact factor: 4.307

4.  The human dystrophin gene requires 16 hours to be transcribed and is cotranscriptionally spliced.

Authors:  C N Tennyson; H J Klamut; R G Worton
Journal:  Nat Genet       Date:  1995-02       Impact factor: 38.330

5.  Dystrophin: the protein product of the Duchenne muscular dystrophy locus.

Authors:  E P Hoffman; R H Brown; L M Kunkel
Journal:  Cell       Date:  1987-12-24       Impact factor: 41.582

Review 6.  Read-through strategies for suppression of nonsense mutations in Duchenne/ Becker muscular dystrophy: aminoglycosides and ataluren (PTC124).

Authors:  Richard S Finkel
Journal:  J Child Neurol       Date:  2010-06-02       Impact factor: 1.987

7.  SILAC mouse for quantitative proteomics uncovers kindlin-3 as an essential factor for red blood cell function.

Authors:  Marcus Krüger; Markus Moser; Siegfried Ussar; Ingo Thievessen; Christian A Luber; Francesca Forner; Sarah Schmidt; Sara Zanivan; Reinhard Fässler; Matthias Mann
Journal:  Cell       Date:  2008-07-25       Impact factor: 41.582

8.  The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy. II. Correlation of phenotype with genetic and protein abnormalities.

Authors:  K M Bushby; D Gardner-Medwin; L V Nicholson; M A Johnson; I D Haggerty; N J Cleghorn; J B Harris; S S Bhattacharya
Journal:  J Neurol       Date:  1993-02       Impact factor: 4.849

9.  Birth and population prevalence of Duchenne muscular dystrophy in The Netherlands.

Authors:  A J van Essen; H F Busch; G J te Meerman; L P ten Kate
Journal:  Hum Genet       Date:  1992-01       Impact factor: 4.132

Review 10.  Emerging genetic therapies to treat Duchenne muscular dystrophy.

Authors:  Stanley F Nelson; Rachelle H Crosbie; M Carrie Miceli; Melissa J Spencer
Journal:  Curr Opin Neurol       Date:  2009-10       Impact factor: 5.710

View more
  24 in total

Review 1.  Stable isotope dilution mass spectrometry for membrane transporter quantitation.

Authors:  Vahid Farrokhi; Adam J McShane; Reza Nemati; Xudong Yao
Journal:  AAPS J       Date:  2013-10       Impact factor: 4.009

2.  Proceedings of the 2017 National Toxicology Program Satellite Symposium.

Authors:  Susan A Elmore; Famke Aeffner; Dinesh S Bangari; Torrie A Crabbs; Stacey Fossey; Shayne C Gad; Wanda M Haschek; Jessica S Hoane; Kyathanahalli Janardhan; Ramesh C Kovi; Gail Pearse; Lyn M Wancket; Erin M Quist
Journal:  Toxicol Pathol       Date:  2017-11-07       Impact factor: 1.902

Review 3.  What is the level of dystrophin expression required for effective therapy of Duchenne muscular dystrophy?

Authors:  Dominic J Wells
Journal:  J Muscle Res Cell Motil       Date:  2019-07-09       Impact factor: 2.698

4.  Dystrophin and mini-dystrophin quantification by mass spectrometry in skeletal muscle for gene therapy development in Duchenne muscular dystrophy.

Authors:  Vahid Farrokhi; Jason Walsh; Joe Palandra; Joanne Brodfuehrer; Teresa Caiazzo; Jane Owens; Michael Binks; Srividya Neelakantan; Florence Yong; Pinky Dua; Caroline Le Guiner; Hendrik Neubert
Journal:  Gene Ther       Date:  2021-11-05       Impact factor: 4.184

5.  Somatic mosaicism due to a reversion variant causing hemi-atrophy: a novel variant of dystrophinopathy.

Authors:  Jaya Punetha; Simin Mansoor; Tulio E Bertorini; Akanchha Kesari; Kristy J Brown; Eric P Hoffman
Journal:  Eur J Hum Genet       Date:  2016-03-09       Impact factor: 4.246

6.  Latent process model of the 6-minute walk test in Duchenne muscular dystrophy : A Bayesian approach to quantifying rare disease progression.

Authors:  Janelle L Lennie; John T Mondick; Marc R Gastonguay
Journal:  J Pharmacokinet Pharmacodyn       Date:  2020-01-20       Impact factor: 2.745

Review 7.  Duchenne and Becker Muscular Dystrophies: A Review of Animal Models, Clinical End Points, and Biomarker Quantification.

Authors:  Kristin Wilson; Crystal Faelan; Janet C Patterson-Kane; Daniel G Rudmann; Steven A Moore; Diane Frank; Jay Charleston; Jon Tinsley; G David Young; Anthony J Milici
Journal:  Toxicol Pathol       Date:  2017-10-03       Impact factor: 1.902

8.  204th ENMC International Workshop on Biomarkers in Duchenne Muscular Dystrophy 24-26 January 2014, Naarden, The Netherlands.

Authors:  Alessandra Ferlini; Kevin M Flanigan; Hanns Lochmuller; Francesco Muntoni; Peter A C 't Hoen; Elizabeth McNally
Journal:  Neuromuscul Disord       Date:  2014-09-11       Impact factor: 4.296

9.  Simultaneous Pathoproteomic Evaluation of the Dystrophin-Glycoprotein Complex and Secondary Changes in the mdx-4cv Mouse Model of Duchenne Muscular Dystrophy.

Authors:  Sandra Murphy; Michael Henry; Paula Meleady; Margit Zweyer; Rustam R Mundegar; Dieter Swandulla; Kay Ohlendieck
Journal:  Biology (Basel)       Date:  2015-06-10

10.  TNF-α-Induced microRNAs Control Dystrophin Expression in Becker Muscular Dystrophy.

Authors:  Alyson A Fiorillo; Christopher R Heier; James S Novak; Christopher B Tully; Kristy J Brown; Kitipong Uaesoontrachoon; Maria C Vila; Peter P Ngheim; Luca Bello; Joe N Kornegay; Corrado Angelini; Terence A Partridge; Kanneboyina Nagaraju; Eric P Hoffman
Journal:  Cell Rep       Date:  2015-08-28       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.